Opinion|Videos|January 17, 2024
Key Takeaways from ASH 2023 in Myelofibrosis and AML
Following their review of updates from clinical trials presented at ASH 2023, the Oncology Brothers provide their key takeaways on recent data in myelofibrosis and acute myeloid leukemia.
Advertisement
Advertisement
Related to this article
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
Real-World Data for Darolutamide vs Abiraterone Triplet Therapy in mHSPC
4
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
5